Oncology and Hematology

Episodes 81-96 of 531

Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
MinuteCE®
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
MinuteCE®
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
0.50 program credits
- Luis Paz-Ares, MD, PhD
0.50 program credits
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
MinuteCE®
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
- Charles Turck, PharmD, BCPS, BCCCP
- Jonathon B. Cohen, MD, MS
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
- Charles Turck, PharmD, BCPS, BCCCP
- Jonathon B. Cohen, MD, MS
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
- Hallie Blevins, PhD.
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Global Oncology Academy
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Global Oncology Academy
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Project Oncology®
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
- Ryan Quigley
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Project Oncology®
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
- Charles Turck, PharmD, BCPS, BCCCP
- Virginia Kaklamani, MD
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Project Oncology®
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
- Jennifer Caudle, DO
- Hope S. Rugo, MD, FASCO
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
- Marlene Mimi Maeusli, PhD.
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Project Oncology®
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
- Paola Marignani, PhD, EMBA
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
Project Oncology®
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Project Oncology®
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Yamshon, MD